Skip to main content
SpringerLink
Log in

Aggressive lymphoma at ASH 2012: new standards and new perspectives

  • short review
  • Published:
memo - Magazine of European Medical Oncology Aims and scope Submit manuscript

Abstract

Recent clinical data presented at the annual meeting of the American Society of Hematology underline the importance of incorporating cytarabine in the induction treatment of younger patients with mantle cell lymphoma, while other trials confirmed the importance of immuno-chemotherapy with rituximab and bendamustine, especially in elderly patients. R-CHOP remains the standard for first line treatment in diffuse large B-cell lymphoma, though, several new therapeutic agents such as lenalidomide and ibrutinib are now tested in clinical trials as single agent or in combination with established therapies. Finally, some new therapeutic options for the unfavorable subset of T-cell lymphoma were presented.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Hermine O, Hoste E, Walewski J, et al. Alternating courses of 3x CHOP and 3x DHAP plus rituximab followed by a high dose ARA-C containing myeloablative regimen and autologous stem cell transplantation (ASCT) increases overall survival when compared to 6 courses of CHOP Plus rituximab followed by myeloablative radiochemotherapy and ASCT in mantle cell lymphoma: final analysis of the MCL younger trial of the European mantle cell lymphoma network (MCL net). Blood. 2012;118 (abstr 151, ASH Annual Meeting Abstracts).

  2. Flinn I, Van der Jagt R, Kahl B, et al. An open-label, randomized study of bendamustine and rituximab (BR) compared with rituximab, cyclophosphamide, vincristine, and prednisone (R-CVP) or rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in first-line treatment of patients with advanced indolent non-Hodgkin’s lymphoma (NHL) or Mantle cell lymphoma (MCL): the bright study. Blood. 2012;118 (abstr 902, ASH Annual Meeting Abstracts).

  3. Kahl B, Li H, Smith MR, et al. Mature results from ECOG study E1405—a phase II study of VcR-CVAD with maintenance rituximab for previously untreated mantle cell lymphoma. Blood. 2012;118 (abstr 153, ASH Annual Meeting Abstracts).

  4. Goy A, Sinha R, Williams ME, et al. Phase II multicenter study of single-agent lenalidomide in subjects with mantle cell lymphoma who relapsed or progressed after or were refractory to bortezomib: the MCL-001 “EMERGE” study. Blood. 2012;118 (abstr 905, ASH Annual Meeting Abstracts).

  5. Wang M, Rule S, Martin P, et al. Interim results of an international, multicenter, phase 2 study of Bruton’s tyrosine kinase (BTK) inhibitor, Ibrutinib (PCI-32765), in relapsed or refractory mantle cell lymphoma (MCL): durable efficacy and tolerability with longer follow-up. Blood. 2012;118 (abstr 904, ASH Annual Meeting Abstracts).

  6. Coiffier B, Lepage E, Briere J, et al. CHOP chemotherapy plus rituximab compared with Chop alone in elderly patients with diffuse large B-cell lymphoma. N Engl J Med. 2002 Jan 24;346(4):235–42.

    Article  PubMed  CAS  Google Scholar 

  7. Pfreundschuh M, Trümper L, Osterborg A, et al. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good prognosis diffuse large B-cell lymphoma. A randomized controlled trial by the MabThera International Trial (MInT) group. Lancet Oncol. 2006 May;7(5):379–91.

    Article  PubMed  CAS  Google Scholar 

  8. Fridrik M, Petzer A, Keil F, et al. Non-pegylated liposomal encapsulated doxorubicin reduces cardiotoxicity in 1st line treatment of diffuse large B-cell lymphoma. Final results of a randomized trial. Blood. 2011;117 (abstr 2676, ASH Annual Meeting Abstracts).

  9. Récher C, Coiffier B, Hajoun C, et al. Intensified chemotherapy with ACVBP plus rituximab versus standard CHOP plus rituximab for the treatment of diffuse large B-cell lymphoma (LNH03-2B): an open label randomized phase 3 trial. Lancet. 2011 Nov 26;378(9806):1858–67.

    Article  PubMed  Google Scholar 

  10. Fridirik M, Hausmaninger H, Linkesch W, et al. CEOP-IMVP-Dexa in the treatment of aggressive lymphomas: an Austrian multicenter trial. J Clin Oncol. 1996 Jan;14(1):227–32.

    Google Scholar 

  11. Nowakowski G, LaPlant B, Reeder C, et al. Combination of lenalidomide with R-CHOP (R2CHOP) is well-tolerated and effective as initial therapy for aggressive B-cell lymphomas—a phase II study. Blood. 2012;118 (abstr 689, ASH Annual Meeting Abstracts).

  12. Chiappella A, Franceschetti S, Castellino A, et al. Rituximab-CHOP21 plus lenalidomide (LR-CHOP21) is effective and feasible in elderly untreated diffuse large B-cell lymphoma (DLBCL): results of phase II REAL07 study of the Fondazione Italiana Linfomi (FIL). Blood. 2012;118 (abstr 903, ASH Annual Meeting Abstracts).

  13. Seymour J, Pfreundshuh M, Coiffier B, et al. The addition of bevacizumab to standard therapy with R-CHOP in patients with previously untreated diffuse large B-cell lymphoma is associated with an increased rate of cardiac adverse events: final analysis of safety and efficacy outcomes from the placebo-controlled phase 3 MAIN study. Blood. 2012;118 (abstr 58, ASH Annual Meeting Abstracts).

  14. Wilson W, Gerecitano J, Goy A, et al. The Bruton’s tyrosine kinase (BTK) inhibitor, Ibrutinib (PCI-32765), has preferential activity in the ABC subtype of relapsed/refractory de novo diffuse large B-cell lymphoma (DLBCL): interim results of a multicenter, open-label, phase 2 study. Blood. 2012;118 (abstr 686, ASH Annual Meeting Abstracts).

  15. Swinnen L, Li H, Quon A, et al. Response-adapted therapy for diffuse large B-cell non-Hodgkin’s lymphoma (DLBCL) based on early [18F] FDG-PET scanning: an eastern cooperative oncology group study (E3404). Blood. 2012;118 (abstr 687, ASH Annual Meeting Abstracts).

  16. Fanale M, Shustov A, Forero-Torres A, et al. Brentuximab vedotin administered concurrently with multi-agent chemotherapy as frontline treatment of ALCL and other CD30-positive mature T-cell and NK-cell lymphomas. Blood. 2012;118 (abstr 60, ASH Annual Meeting Abstracts).

  17. d’Amore F, Leppä S, Gomes da Silva M, et al. First interim efficacy and safety analysis of an international phase III randomized trial in newly diagnosed systemic peripheral T-cell lymphoma treated with chemotherapy with or without Alemtuzumab and consolidated by high dose therapy. Blood. 2012;118 (abstr 57, ASH Annual Meeting Abstracts).

Download references

Conflict of interest

The authors declare that there are no actual or potential conflicts of interest in relation to this article.

Author information

Authors and Affiliations

  1. 3rd Medical Department for Hematology and Oncology, Hanusch Krankenhaus, 1140, Heinrich Collinstrasse 30, Vienna, Austria

    Thomas Nösslinger MD

Authors
  1. Thomas Nösslinger
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Thomas Nösslinger MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Thomas Nösslinger MD.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Nösslinger, T., Nösslinger, T. Aggressive lymphoma at ASH 2012: new standards and new perspectives. memo 6, 170–173 (2013). https://doi.org/10.1007/s12254-013-0086-8

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12254-013-0086-8

Keywords

Search

Navigation